Displaying drugs 11576 - 11600 of 12789 in total
ALX-009
Investigational
DYN-101
DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.
Investigational
AMT-162
AMT-162 is an adeno-associated virus serotype rh10 encoding artificial anti-SOD1 miRNA.
Investigational
TTAX01
TTAX01 is a cryopreserved human umbilical cord product being developed by TissueTech.
Investigational
Debamestrocel
Debamestrocel consists of autologous mesenchymal stromal cells secreting neurotrophic factors. Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Investigational
ALMB-0166
ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.
Investigational
Suvodirsen
Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Bepranemab
Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.
Investigational
RTL-1000
RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.
Investigational
Recombinant human palmitoyl-protein thioesterase-1
Investigational
SPK-1001
Investigational
PLX-PAD
Investigational
AMB-301
AMB-301 is an AAV gene therapy delivering E-selectin. It is under investigation for the treatment of Buerger disease.
Investigational
NX001
Investigational
BZ371A
Investigational
PLG-0206
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
PHE885
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Anti-CD7 CAR T-cell therapy
Investigational
OTOF-GT
OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated with otoferlin deficiency.
Investigational
DYNE-251
DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
Investigational
PMC-403
PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.
Investigational
DS-2325a
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Investigational
Xaluritamig
Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.
Investigational
SBT101
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Displaying drugs 11576 - 11600 of 12789 in total